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Significance of this study
What is already known about this subject?
 ► Diabetes and its complications accounts for a signif-
icant proportion of costs in any health service, gen-
erating large quantities of carbon dioxide.
 ► Minimizing health service- associated carbon dioxide 
emissions is a priority to help prevent further global 
warming.
What are the new findings?
 ► We have used an established model to show that 
maintaining or reducing glycated hemoglobin con-
centrations reduces carbon dioxide equivalent 
emissions compared with those with unchanging 
glycemic control.
How might these results change the focus of 
research or clinical practice?
 ► This model can be used as a template for other long- 
term conditions to assess the environmental impact 
of treatments on a national basis.
AbStrAct
Background The management of diabetes- related 
complications accounts for a large share of total carbon 
dioxide equivalent (CO2e) emissions. We assessed whether 
improving diabetes control in people with type 2 diabetes 
reduces CO2e emissions, compared with those with 
unchanging glycemic control.
Methods Using the IQVIA Core Diabetes Model, we 
estimated the impact of maintaining glycated hemoglobin 
(HbA1c) at 7% (53 mmol/mol) or reducing it by 1% (11 
mmol/mol) on total CO2e/patient and CO2e/life- year (LY). 
Two different cohorts were investigated: those on first- line 
medical therapy (cohort 1) and those on third- line therapy 
(cohort 2). CO2e was estimated using cost inputs converted 
to carbon inputs using the UK National Health Service’s 
carbon intensity factor. The model was run over a 50- year 
time horizon, discounting total costs and quality adjusted 
life years (QALYs) up to 5% and CO2e at 0%.
Results Maintaining HbA1c at 7% (53 mmol/mol) reduced 
total CO2e/patient by 18% (1546 kgCO2e/patient) vs 13% 
(937 kgCO2e/patient) in cohorts 1 and 2, respectively, and 
led to a reduction in CO2e/LY gain of 15%–20%. Reducing 
HbA1c by 1% (11 mmol/mol) caused a 12% (cohort 1) and 
9% (cohort 2) reduction in CO2e/patient with a CO2e/LY 
gain reduction of 11%–14%.
Conclusions When comparing people with untreated 
diabetes, maintaining glycemic control at 7% (53 mmol/
mol) on a single agent or improving HbA1c by 1% (11 
mmol/mol) by the addition of more glucose- lowering 
treatment was associated with a reduction in carbon 
emissions.
InTRoduCTIon
The global prevalence of diabetes mellitus has 
been estimated to increase from 463 million 
in 2019 to 700 million (20–79 years) by 2045.1 
The management of diabetes and its complica-
tions imposes a significant economic burden 
on society.2 3 In addition, the healthcare 
sector is a significant contributor to the nega-
tive impact on the environment. In England, 
healthcare provision is associated with an 
estimated annual emission of 22.8 million 
tons of carbon dioxide equivalent (CO2e).
4 A 
huge proportion of carbon emissions (58.3% 
in 2015) come from the goods procured 
by the National Health Service (NHS) in 
England, with pharmaceuticals estimated to 
contribute up to 15.3% of the NHS’s carbon 
footprint.4 Despite an increasingly aging 
population and a corresponding increase in 
demand for resources, together with a legal 
commitment to reduce its carbon footprint 
by 80% by 2050, the NHS has emphasized 
the importance of sustainable healthcare.4 5 
However, what remains unknown is whether 
improving markers of chronic disease will 
have an impact on the carbon footprint. In 
this study, a novel approach was taken to map 
the link between healthcare and carbon emis-
sion associated with the management of type 
2 diabetes mellitus (T2DM).
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MeTHods
Approach and assumptions
A previously validated clinical economic model—the IQVIA 
Core Diabetes Model (CDM)—was used to estimate the 
carbon footprint for the analysis.6 This used data based on 
the UK Prospective Diabetes Study cohorts. Two scenarios 
were considered to map the impact of effective diabetes 
management on carbon emission in people with T2DM in 
the UK when compared with those who were untreated.
 ► Maintaining a glycated hemoglobin (HbA1c) concen-
tration of 7.0% (53 mmol/mol) (scenario 1).
 ► Reducing HbA1c concentration by 1.0% (11 mmol/
mol) from baseline (scenario 2).
Each scenario was simulated on two sets of cohorts: 
people with diabetes on first- line medical therapy and 
those on third- line therapy (defined in the Study popu-
lation section). The point estimates for each simulated 
end point were obtained from the CDM by averaging 
the model’s output over 1000 simulation replications. We 
analyzed three outcomes in the study: overall reduction 
in carbon emission per patient (kgCO2e/patient), reduc-
tion in carbon emission per life- year gained (kgCO2e/LY), 
and improvement in life- year gained. In both scenarios, 
in order to achieve ‘treatment neutrality’, interventions 
such as pharmacological or other therapies used to achieve 
outcomes were not evaluated in the assessment of carbon 
emission. This allowed an assessment of the relationship 
between glycemic control and carbon emission by main-
taining all other variables constant, including the cost of 
diabetes treatment.
The assumptions regarding carbon emission were 
derived from the NHS Goods and Services Carbon 
Hotspots report that estimated the amount of carbon 
dioxide (CO2) produced from NHS activities.
7 The 
carbon footprint was assessed using CO2 equivalents 
(kgCO2e) for the resources used in the management 
of T2DM complications. A time horizon of 50 years was 
considered. Future clinical health benefits and costs were 
converted to present values using a constant discount 
rate of 5% per year, while the CO2 discount rate was kept 
at 0% for intergenerational equity reasons.
estimation of carbon emission related to T2dM complications
The factors related to diabetes management were disag-
gregated into healthcare resources and services (such 
as general practitioner visits and specialist clinic visits). 
These resources/services were broken down into broad 
sources of carbon emission (eg, building energy, patient 
travel), which were further segregated into relevant 
components and activities (eg, medication, equipment). 
Each unit of activity or resource derived from this break-
down was assigned an associated cost obtained from the 
NHS Reference Costs,8 the British National Formulary, 
and the Personal Social Services Research Unit (PSSRU).9 
All costs were then converted to 2016 prices by applying 
inflation/price index (eg, consumer price index). The 
weighted number of services used (and their costs) was 
estimated by multiplying the annual number of units 
used (costs) by the proportion of people receiving those 
services. The carbon footprint was derived by multiplying 
the carbon intensity values obtained from the NHS 
Hotspot report7 by the weighted number of services used 
(online supplementary table A).
An alternate assessment of carbon burden
A sensitivity analysis of cost inputs used to estimate the 
carbon burden was performed to validate base case 
assumptions. A systematic literature review was conducted 
to derive the cost of managing diabetes complica-
tions.10–16 All the costs were adjusted for 2016 using an 
inflation rate provided in the PSSRU for each complica-
tion.13 These costs were then used to deduce their corre-
sponding carbon emission by multiplying them with a 
carbon intensity factor of 0.23 kgCO2e/£ (online supple-
mentary table A). In the sensitivity analysis, we simulated 
the cost inputs from the systematic literature review into 
the IQVIA CDM and compared the results with the base 
case in which the cost inputs were previously provided.8 9
In the base case, clinical discounting was taken as 5%. A 
sensitivity analysis was also performed with discount rates 
of 2.5% and 3.5% while maintaining CO2 discounting at 
0%. The sensitivity analysis based on the discount rates 
was performed for both sets of cost inputs, that is, those 
obtained from NHS Reference Costs/PSSRU and the liter-
ature review.
Model
A brief overview of the IQVIA CDM is provided here and 
a detailed description of the model has been previously 
published.17 The model is designed in a modular way, 
which permits customization of analyses by facilitating new 
clinical data, treatment effect, cost and quality of life, and 
patient management data where and when necessary for 
type 1 and type 2 diabetes cohorts. The model includes 
various cost parameters, namely pharmacy, costs associated 
with screening, treatment procedures for microvascular 
and macrovascular complications, and management of 
end- stage complications. A series of submodels are used to 
simulate the occurrence of diabetes- related complications, 
including angina, myocardial infarction, congestive heart 
failure, stroke, peripheral vascular disease, diabetic reti-
nopathy, macular edema, cataract, hypoglycemia, diabetic 
ketoacidosis, lactic acidosis, nephropathy, neuropathy, foot 
ulcers and amputations, and mortality, over a range of 
time horizons. As such the complications were defined in 
terms of interventions for these complications focusing on 
hospital admissions and, for example, the need for surgery, 
and the carbon equivalents of such resource requirements. 
As such the model also allows users to undertake cost- 
effectiveness and cost- utility analyses.
study population
The patient population used in the model was represen-
tative of the T2DM adult population in the UK, treated 
according to the guideline from the National Institute 
for Health and Care Excellence.18 Two specific patient 
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Figure 1 Reduction in total carbon emission per patient. CO2e, carbon dioxide equivalent.
cohorts were considered, namely people with diabetes on 
first- line medical therapy and those on third- line therapy 
attending hospital clinic appointments.
Cohort 1: first-line medical therapy
This cohort consisted of individuals whose diabetes was 
not adequately controlled by exercise and/or diet and 
therefore required therapeutic intervention. These people 
were assumed to be treated with one oral antidiabetic drug 
(OAD) for initial management of diabetes (eg, metformin).
Cohort 2: third-line medical therapy
This cohort consisted of people whose diabetes remained 
uncontrolled with a combination of two OADs or an OAD 
with a glucagon- like peptide-1 (GLP-1) agonist. These 
people were assumed to be treated with triple therapy (any 
three OADs, two OADs with a GLP-1 agonist, or insulin 
with any other drugs). This cohort was chosen rather than 
the more common second- line escalation because indi-
viduals who require such escalations are often referred 
to secondary care. This means that there is likely to be 
increased carbon footprint. This difference between first- 
line and third- line treatment was also felt to most likely 
demonstrate a greater difference in effect than the simple 
addition of second- line therapy in the primary care setting.
ResulTs
Baseline characteristics
The mean age in cohort 1 was 59.8 years and 57.1% were 
male, while in cohort 2 the mean age was 64.5 years and 
55.8% were male (online supplementary table B). The 
baseline characteristics of both cohorts were comparable 
in terms of mean systolic blood pressure (137.5 mm Hg 
vs 136.2 mm Hg), mean total cholesterol (4.96 mmol/L 
vs 4.36 mmol/L), and mean body mass index (31.9 kg/
m2 vs 30.5 kg/m2). The average duration since diagnosis 
was 2 years and 9 years, respectively, for the two cohorts.
Cohort 2 included a higher proportion of comorbidities, 
including myocardial infarction, stroke, and congestive 
heart failure, while the proportion of individuals with 
atrial fibrillation was relatively higher in cohort 1. The inci-
dence of other cardiovascular complications (eg, periph-
eral vascular disease and left ventricular hypertrophy) 
was comparable in both cohorts, although cohort 2 had a 
higher proportion of people with end- stage renal disease.
Modeling results
Reduction in carbon emission due to active treatment
Figure 1 represents the reduction in kgCO2/patient for 
both scenarios in comparison with untreated people with 
T2DM. When HbA1c concentration was maintained at 
7.0% (53 mmol/mol) (scenario 1), a higher per patient 
reduction in CO2e was observed in cohort 1 compared 
with cohort 2 (18% (1546 kgCO2e/patient) vs 13% (937 
kgCO2e/patient)). Similarly, when considering a reduc-
tion in HbA1c concentration by 1.0% (11 mmol/mol) 
from baseline (scenario 2), cohort 1 showed a greater 
CO2e reduction of 12% (1049 kgCO2e/patient) as 
compared with a CO2e reduction of 9% (655 kgCO2e/
patient) in cohort 2.
Table 1 describes the outcomes of both scenarios on 
the reduction in kgCO2e/LY and life year gained as 
compared with untreated people with T2DM. In scenario 
1, a 3.0% and 2.0% improvement in life- year gained was 
observed for individuals on first- line therapy and those 
on third- line therapy, respectively. In scenario 2, a 1.9% 
improvement in life- year gained was observed in both 
cohorts. The reduction in carbon emission per life- year 
gained (kgCO2e/LY) on maintaining HbA1c concentra-
tion at 7.0% (53 mmol/mol) was 20% and 15% in cohort 
1 and cohort 2, respectively. On the other hand, reducing 
HbA1c concentration by 1.0% (11 mmol/mol) led to a 
reduction of 14% and 11% of carbon emission per life- 
year gained, respectively (table 1).
Contributing factors to reduction in carbon emission
Maintenance or improvement of glycemic control 
reduced carbon emission, although the degree of 
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Table 1 Carbon burden associated with diabetes complication management
Cohort
Life- years Carbon emission (kgCO2e/LY)
Baseline Scenario 1 Scenario 2 Baseline Scenario 1 Scenario 2
Cohort 1 10.58 10.88 (−3.00%) 10.79 (−1.90%) 834.16 669.63 (−20.00%) 721.27 (−14.00%)
Cohort 2 9.39 9.62 (−2.00%) 9.57 (−1.90%) 782.27 666.18 (−15.00%) 699.10 (−11.00%)
Figures in parentheses represent the percentage of improvement in (reduction in) carbon/cost levels from baseline.
Scenario 1: HbA1c concentration maintained at 7% (53 mmol/mol) throughout model simulation.
Scenario 2: HbA1c reduced by 1% (11 mmol/mol) point from baseline.
Cohort 1: patients on first- line therapy.
Cohort 2: patients on third- line therapy.
Baseline: results obtained when the respective cohorts were treated with the comparator (placebo/no therapy).
HbA1c, glycated hemoglobin; kgCO2e/LY, carbon dioxide equivalent per life- year.
Figure 2 Factors responsible for reduction in total carbon emission per patient. *Components of management- related 
carbon emission include concomitant medication (statins, ACE inhibitors, and so on), screening, and patient management and 
preventive programs. CVD, cardiovascular disease; kgCO2e, carbon dioxide equivalent.
reduction varied by which complications were prevented 
(figure 2). In both scenarios, the largest contributor to 
the reduction in overall CO2e was the prevention of renal 
complications. When HbA1c concentration was main-
tained at 7.0% (53 mmol/mol), carbon emission related 
to renal complications reported a 54% (955 kgCO2e/
patient) reduction in cohort 1 and 34% (504 kgCO2e/
patient) reduction in cohort 2. Similarly, the reduction 
in HbA1c concentration by 1.0% (11 mmol/mol) from 
baseline led to a reduction in carbon emission associated 
with renal complications by 40% (708 kgCO2e/patient) 
in individuals on first- line therapy and by 27% (396 
kgCO2e/patient) in those on third- line therapy.
sensitivity analysis
Alternate cost inputs for assessing carbon burden
Sensitivity analyses done using previously published costs 
were comparable with the results obtained in the base case 
analysis (figure 3). In the sensitivity analysis, when HbA1c 
concentration was maintained at 7.0% (53 mmol/mol), 
first- line medical therapy led to a reduction of 15% (1386 
kgCO2e/patient) in carbon emission levels, while third- 
line therapy resulted in an 11% reduction (786 kgCO2e/
patient). When HbA1c concentrations were reduced by 
1.0% (11 mmol/mol), first- line therapy reduced carbon 
emission by 11% (979 kgCO2e/patient), while third- line 
therapy led to 8% reduction (589 kgCO2e/patient).
Figure 4 illustrates the contribution of individual T2DM 
complication management responsible for the overall 
reduction in kgCO2e/patient in the sensitivity analysis. 
Similar to the base case, reduction in carbon emission 
associated with renal complications was the major driver 
for the overall reduction in CO2e. When HbA1c concen-
tration was maintained at 7.0% (53 mmol/mol), carbon 
emission related to renal complications reduced by 54% 
in cohort 1 and 34% in cohort 2, similar to reductions 
seen in the base case. On reduction of HbA1c concentra-
tion by 1.0% (11 mmol/mol), renal complication- related 
carbon emission reduced by 40% in cohort 1 and 27% in 
cohort 2 (figure 4).
Clinical discounting rate as a variable
Sensitivity analyses performed on the discount rates of 
2.5% and 3.5% showed that the higher the discount rate 
chosen, the larger the reduction in kgCO2e/LY (online 
supplementary figure S5 and S6). When discounting 
was reduced from 5.0% to 3.5%, reduction in CO2e/
LY gained decreased by an average of 10%, and when 
reduced from 5.0% to 2.5% it decreased by an average of 
17%. A lower reduction in CO2/LY observed here despite 
copyright.
 o
n
 April 30, 2020 at University of East Anglia. Protected by
http://drc.bmj.com/
BM
J O
pen Diab Res Care: first published as 10.1136/bmjdrc-2019-001017 on 16 April 2020. Downloaded from 
5BMJ Open Diab Res Care 2020;8:e001017. doi:10.1136/bmjdrc-2019-001017
Epidemiology/Health Services Research
Figure 3 Reduction in total carbon emission per patient as calculated with inputs from systematic literature review only. 
Baseline: results obtained when the respective cohorts were treated with the comparator (placebo/no therapy); scenario 1: 
HbA1c concentration maintained at 7% (53 mmol/mol) throughout model simulation; scenario 2: HbA1c permanently reduced by 
1% (11 mmol/mol) point from baseline; cohort 1: patients on first- line therapy; cohort 2: patients on third- line therapy. CO2e, 
carbon dioxide equivalent; HbA1c, glycated hemoglobin.
Figure 4 Factors responsible for reduction in total carbon emission per patient as calculated with inputs from systematic 
literature review only. *Components of management- related carbon emission include concomitant medication (statins, ACE 
inhibitors, and so on), screening, and patient management and preventive programs. Baseline: results obtained when the 
respective cohorts were treated with the comparator (placebo/no therapy); scenario 1: HbA1c concentration maintained at 7% 
(53 mmol/mol) throughout model simulation; scenario 2: HbA1c permanently reduced by 1% (11 mmol/mol) point from baseline; 
cohort 1: patients on first- line therapy; cohort 2: patients on third- line therapy. CVD, cardiovascular disease; HbA1c, glycated 
hemoglobin; kgCO2e, carbon dioxide equivalent.
the lower discounting rate was attributed to the CO2 
discounting rate being maintained at 0% for both treated 
as well as untreated individuals (which causes no changes 
to CO2). This led to an increase only in the denominator 
at a lower discounting rate, which ultimately led to a 
lower reduction in CO2e/LY gained.
dIsCussIon
Main findings of this study
This study has addressed the environmental impact that 
T2DM management has in the UK. Our study has shown 
that maintaining or improving glycemic control has poten-
tial environmental benefits. This study complements an 
initiative by the NHS Sustainable Development Unit to 
evaluate the environmental consequences of patient care 
and to reduce NHS- related greenhouse gas emission by 
80%.
What is already known on this topic
While there are a number of data to show that good 
diabetes control makes a difference to the risk of devel-
oping diabetes- related complications, this study shows 
that in addition to improving outcomes on an individual 
basis, there are wider population benefits from achieving 
glycemic targets.
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What this study adds
Most of the published work on climate change focuses 
on the negative impact of greenhouse gas emissions on 
human health. Kan19 described the contribution of heat-
waves to morbidity and mortality from infectious respira-
tory diseases, while Reacher et al20 reported a significant 
increase in the risk of gastroenteritis due to flooding 
in Southern England. According to the WHO, climate 
change is expected to cause approximately 250 000 addi-
tional deaths per year due to malnutrition, malaria, diar-
rhea, and heat stress between 2030 and 2050.21 However, 
unlike most previous work, the current study focuses on 
the association between healthcare interventions and the 
environment. A recent study has proposed a method for 
incorporating the environmental impact into a health 
economic analysis.22 The current study corroborates the 
findings of those authors by emphasizing the importance 
of accounting for the environmental impact of improving 
glycemic control in the reduction of CO2 emission.
The UK NHS has developed a strategy for minimizing 
its environmental impact, including a hotspot refer-
ence manual for individual health resources used.7 In 
this study we have applied it in an existing economic 
model, substituting costs for carbon output in a hypo-
thetical cohort of people with T2DM. All the scenarios 
analyzed in the study show that maintaining or improving 
adequate glycemic control in people with T2DM is asso-
ciated with a reduction in carbon emissions. The highest 
reduction in CO2e/patient and CO2e/LY was observed 
in people on first- line therapy whose HbA1c concentra-
tion was maintained at 7.0% (53 mmol/mol). Thus, in 
addition to reducing the likelihood of developing micro-
vascular and macrovascular complications, maintaining 
good glycemic control maximizes reduction in carbon 
emission.
In this study, the reduction in renal complication rates 
was the major contributor to the overall CO2e reduction. 
Those on first- line therapy showed a greater reduction in 
renal complications as compared with those on third- line 
therapy. This can be attributed to a lower incidence of 
renal complications in those on first- line therapy only.23 
Those who maintained lower initial HbA1c concentrations 
would have a more carbon- efficient outcome compared 
with less aggressively treated individuals in whom HbA1c 
became raised, who progressed to renal impairment, or 
who developed other complications.
The importance of incorporating environmental 
benefits has also been reinforced by the International 
Diabetes Federation in its Diabetes and Climate Change 
Report, which states that ‘inefficient management of 
diabetes can lead to increased demands on health 
services and further escalate their already large carbon 
footprint’.24 In the UK, data from the 2017 National 
Diabetes Inpatient Audit showed that approximately 
18% of all inpatient beds are occupied by someone with 
diabetes.25 These individuals are most frequently not in 
hospital due to diabetes but have diabetes in addition to 
their underlying diagnosis. They are often in hospital for 
longer than those without diabetes admitted for the same 
condition and suffer more harm as a result of relatively 
poor management of their diabetes while in hospital.26 27 
Thus, having diabetes as an inpatient, whether as a direct 
result of diabetes- related complications or not, is energy- 
intensive and increases greenhouse gas emissions.28 This 
analysis also acts as a framework for future studies to 
assess the impact of interventions on glycemic control, 
resource utilization, and the corresponding carbon emis-
sion reduction. Additionally, by considering sustained 
reductions in HbA1c concentration, future studies can 
assess the maximum potential of improved patient health 
on NHS carbon reduction.
limitations of this study
The results of this study should be interpreted carefully 
until validated on a wider diabetes population. The 
current study only quantifies the reduction of carbon 
emission in the modeled population but does not deter-
mine its statistical significance, which is a key limitation. 
Furthermore the model does not take into account inter-
ventions needed to achieve lower HbA1c concentrations 
in the assessment of carbon emissions. This may have 
led to the results biasing the benefits of lower HbA1c 
without also modeling the increased emissions associated 
with achieving such control. However, we had made an 
a priori decision to test the novel modeling and not the 
mode of treatment. For example, specific pharmacy costs 
were not included directly (because the study was drug 
agnostic), but drug treatment would have been included 
in the overall costs per bed day and these then appor-
tioned across all inpatients with diabetes. With these 
assumptions, there is a possibility that we have overesti-
mated the benefits of lowering HbA1c because it is being 
accomplished without any carbon emission. This could 
bias our results, but it is unclear to what magnitude. 
We accept that the model is not perfect, and we could 
have potentially limited the time horizon to 10 years, but 
feel that the current data are a place to start, and as the 
complexity within the model improves more appropriate 
considerations can be factored into it.
In addition, our study assumes that once HbA1c 
concentration is reduced, it will remain at that level. We 
accept that this is contrary to what is seen in the real- 
world setting,29 but for the purpose of this modeling 
exercise we made this assumption. By analyzing two 
distinct cohorts of people with T2DM, we aimed, in a 
simple way, to demonstrate the potential carbon emis-
sion savings along the treatment pathway. There is also 
the assumption that by either maintaining glycemic 
control at 7% (53 mmol/mol) or reducing it by 1% 
(11 mmo/mol), this will not cause harm. The Action 
to Control Cardiovascular Risk in Diabetes trial looked 
to intensify glycemic control in those with a mean age 
at entry of 62.2 years to below 6.0% (43 mmol/mol) 
compared with those receiving ‘standard of care’, that 
is, aiming to achieve an HbA1c of between 7.0% and 
7.9% (53–64 mmol/mol).30 This study was stopped early 
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due to the statistically significant 22% increased risk of 
mortality in the intensive treatment group.30 However, 
this increased risk has not been shown in other trials.31 32 
In addition, there is an argument to be made to run a 
further analysis to assess the effect of individualization 
for HbA1c targets, as recommended by the UK National 
Institute for Health and Care Excellence and the Amer-
ican Diabetes Association.18 33 However, this was not 
the focus of this work because our aim was to test this 
approach to find differences in CO2 output reductions 
according to resource intensity, and not mirror national 
policies or recommendations.
One observation is that the two methods of generating 
kgCO2e values for individual complications do not give 
consistent results. Some values are similar across the two 
methods (eg, for the cardiovascular events) but some 
are quite different. This suggests that the quantification 
of the carbon footprint of individual NHS activities is 
not yet robust. Wider use of this kind of analysis would 
benefit from more accurate measurement of the NHS’s 
current carbon emissions.
Another limitation was the omission of pharmacolog-
ical therapies from the model. This was done to keep the 
model as simple as possible. The addition of therapies 
would have made the model more complicated.
Despite these limitations, the study represents a new 
robust methodology to ascertain the environmental 
impact of managing a chronic condition such as diabetes.
This is an important development to adopt in health-
care, since we have shown that for an individual who 
maintains their HbA1c,using published data on carbon 
production in car driving, the emissions avoided (955 
kgCO2e/patient) equate to not driving 7908 km over 
a lifetime,34 or 9 months of energy expenditure of the 
average UK household.35 While we have not scaled this 
to a national level, an approximation can be made. In 
UK, 66.5% of 3.5 million people with diabetes have 
HbA1c <7.5%,36 of whom 90% have T2DM.37 Hence, 
the UK prevalence for well- controlled T2DM is 2.1 
million.
Using published data on carbon production in car 
driving, the emissions avoided (955 kgCO2e/patient) 
equate to not driving 4914 miles (7908 km) over a life-
time, or 9 months of energy expenditure of the average 
UK household. Equating the data on emissions avoided 
(ie, 7908 km not driven) to the national estimate for 
people with controlled T2DM, this would imply 2 billion 
kgCO2e emissions avoided, by not driving 10 billion 
miles (17 billion km). Data from the UK Department 
for Transport states that in 2018 there were 808 billion 
passenger kilometers traveled by 66 million people in 
the UK, 83% (670 billion km) of which were by car, van 
or taxi.38 Using this calculation, if glycemic control were 
to be maintained in the 2.1 million people with T2DM 
and an HbA1c <7.5% (58 mmol/mol), then almost 21 
billion kilometers of motor vehicle travel by people with 
diabetes could be saved.
ConClusIon
This study is novel in its approach because it models one 
possible outcome (of maintaining appropriate glycemic 
control) which, if achieved, could potentially reduce 
carbon emission. Environmental burden analysis is likely 
to become an integral part of health economic evaluation 
in the near future. Our findings highlight that effective 
glycemic control and avoidance of diabetes complica-
tions can reduce NHS carbon emission by 10%–20% 
per life- year gained. These data showcase the potential 
benefits to the environment of keeping diabetes under 
control. This approach of estimating carbon emission 
represents a simple yet important measure to assess the 
environmental burden attributed to healthcare manage-
ment. In addition, the study evaluates the impact of 
effective glycemic management on the environment 
irrespective of any specific treatment recommendation. 
This approach could be extended to many other areas 
to analyze the carbon effectiveness that can be achieved 
through appropriate disease management.
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